Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Nicholas Parker as Executive Vice President, Worldwide Field Operations, effective August 24, 2026, along with detailed compensation terms including a $1M base salary, $5M sign-on bonus, and $40M in equity grants. While the section also mentions Ajay K. Puri's retirement, the principal disclosed action centers on Parker's appointment to a senior executive role with material compensation arrangements. This is a significant leadership transition at a major technology company and would affect investor assessment of operational continuity and capital allocation.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-02
The filing announces the appointment of Mr. Botao Shi as interim chief financial officer of Concord Medical, effective June 30, 2026. While the filing also discloses the resignation of the prior CFO, Mr. Wei Jiang, the principal disclosed action is the appointment of a new CFO to fill that role. The appointment of a CFO is a material executive change affecting the registrant's financial leadership and would affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses both a director departure (David Sambur's resignation effective July 2, 2026) and a director appointment (Christine Duffy's appointment to fill the vacancy). While both events occur, the principal disclosed action centers on the appointment of Ms. Duffy to the board, with her qualifications, compensation terms, and indemnification agreement detailed. The departure is presented as a mechanical consequence of Apollo Investors' reduced designation rights following their public offering. The appointment of a qualified director with significant hospitality industry experience is the substantive event requiring investor attention.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-02
EX-99.1
The exhibit announces the appointment of Ms. Xiaojing Lu as a director and member of two board committees, effective July 1, 2026. Although the announcement also discloses the concurrent resignation of Ms. Yifang Xu, the principal disclosed action is the appointment of a new director with significant internal operational experience and board committee responsibilities. This is a material governance event affecting board composition.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-02
EX-99.1
The exhibit announces the appointment of Mr. Ying Tian as Chief Financial Officer of iQIYI, effective immediately. This is a material executive appointment to a named officer position (CFO), which would affect a reasonable investor's assessment of the company's financial leadership and governance. The concurrent step-down of Ms. Ying Zeng from Interim CFO is secondary to the principal appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
The disclosure centers on the election of Tali Farhadian Weinstein to the Board of Directors of Consolidated Edison, Inc. and Consolidated Edison Company of New York, Inc., effective July 1, 2026. She was also appointed to two board committees. This is a clear board appointment, which is a material governance event affecting the composition of the registrant's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
Francis A. Braun III and Dylan G. Petre were appointed to the Board of Directors effective July 1, 2026 upon listing, with Braun designated as Audit Committee chair and Petre appointed to the Nominating and Corporate Governance Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
Michael Blitzer was appointed as director and Chairman of the Board, and Kevin Shannon was appointed as Chief Executive Officer, both effective June 26, 2026, in connection with the Business Combination Agreement with Inflection Point Asset Management LLC.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 83%
filed 2026-07-02
Item 5.02
Dr. Craig Eagle was appointed to OS Therapies' Board of Directors effective June 1, 2026, transitioning from Chief Medical Advisor. Dr. Eagle brings substantial oncology and pharmaceutical leadership experience, including prior roles as CMO at Guardant Health, VP Medical Affairs at Genentech, and senior positions at Pfizer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
The Board appointed Joanna Lohkamp as an interim director, Audit Committee member, and Remuneration Committee chair, effective July 1, 2026. This is a clear executive/board appointment that would materially affect investor assessment of the company's governance and leadership structure, particularly given her committee roles overseeing audit and compensation matters.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-02
The filing discloses both the resignation of Mark Pickering as CFO and Executive Officer (effective June 29, 2026) and the appointment of Carrie Rosorea as CFO and Executive Officer on the same date. While both events occur, the principal disclosed action is the appointment of a new CFO to fill the vacancy, making exec_appointment the primary classification. CFO changes are material to investors assessing management continuity and financial oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
Dr. David S. Shields was appointed as a Class I director and Compensation Committee member of CapsoVision, Inc., effective July 1, 2026, bringing deep clinical expertise in capsule endoscopy to the Board. The appointment also coincided with Dr. Joanne Imperial's resignation from the Board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-02
Item 8.01
The disclosure centers on the Board's appointment of Elizabeth Hurlburt to a newly created role of Chief Operating and Commercial Officer with expanded functional oversight of commercial functions, medical affairs, regulatory and clinical. While Michael Seckler's departure is mentioned, the principal action disclosed is Hurlburt's appointment to an expanded executive position. The expansion of her role and new title constitute a material change in executive leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
Matthew S. Diffley was appointed as Principal Accounting Officer (PAO) of Live Oak Bancshares, Inc., effective July 1, 2026, replacing interim PAO Walter J. Phifer. While the disclosure also mentions an expected RSU grant of $200,000, the principal disclosed action is the appointment of a named executive to a key officer role. The appointment of a PAO is material to investors as it affects the registrant's financial reporting and internal controls oversight.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-02
The 6-K discloses the appointment of Mr. Tee Kok Siong as Chief Financial Officer of Ryde Group Ltd, effective July 3, 2026, to fill the vacancy created by Mr. Lang Chen Fei's resignation. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite officer role, which is material to investors assessing the company's financial leadership and governance. The detailed biographical information and professional qualifications provided underscore the materiality of this executive transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
The filing discloses the appointment of two directors, Danina Fisher and Gary S. Stetz, II, to the Board of Directors of Hepion Pharmaceuticals, effective immediately on July 1, 2026. This is a clear executive appointment under Item 5.02, with the principal disclosed action being persons taking board roles. The disclosure notes a family relationship between Mr. Stetz and Gary Stetz (the interim CEO signing the filing), which adds governance significance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
UPAY, Inc. appointed Wynand Johannes Jordaan as a non-executive director effective July 1, 2026. The appointment includes a compensatory arrangement of 200,000 restricted shares vesting over 24 months and is intended to strengthen the board's technology, software architecture, systems design, and digital infrastructure expertise.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 88%
filed 2026-07-02
Item 5.02
Lucid announced multiple senior executive appointments to its Global Leadership Team, including Alexander De Bock as Chief Financial Officer (with $750,000 base salary, $1.1M signing bonus, $7.5M equity grants, and up to $2.5M performance-based bonuses), Raja Ramana Macha as Chief Technology Officer, Billy Hayes as Chief Customer Officer, Hugo Martinho as Chief Transformation Officer, Kay Stepper as Chief Digital Officer, and a promotion of Christian Appel, alongside the departure of incumbent CFO Taoufiq Boussaid. These appointments are intended to simplify the organization, sharpen accountability, and improve execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses multiple executive appointments effective July 1, 2026: Robert Wright appointed Chief Financial Officer (replacing Mark Hobbs), Misty Lavender appointed Executive Vice President, General Counsel and Corporate Secretary (replacing Denise McWatters), and Mohit Bhardwaj appointed to a new Executive Vice President, New Energy role. While the section also includes compensation amendments and a departure (McWatters transitioning to consulting), the principal disclosed actions center on the appointments of new officers to key leadership positions, making exec_appointment the most salient classification.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-02
EX-99.1
The press release announces the appointment of Marvin Singer to the board of directors as the representative for Ataraxia Capital, pursuant to an Investor's Rights Agreement. This is a clear executive/governance appointment of a director with relevant experience in corporate law, M&A, and corporate governance. Board appointments are material to investors as they affect governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
Simon Kearney was elected to Nixxy's Board of Directors on June 29, 2026. The disclosure centers on his appointment as a director and includes his background, compensation structure (50,000 initial shares, annual equity grants, and $2,500 monthly payment), and confirmations of no conflicts or family relationships. This is a clear director appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointments of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointment of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the fund manager) on an interim basis, effective July 2, 2026, with Masci also appointed to the Board of Managers and as Principal Financial and Accounting Officer of the registrant. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointments of two executives to critical financial leadership roles. This is material as it affects the fund's financial oversight and reporting structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as CFO appointments directly affect investor confidence in financial reporting and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointment of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-02
Item 5.02
The filing discloses two director-level events: the resignation of Dr. Ming-Fu Chiang on June 27, 2026, and the election of Nasim Shomali as a Class II director on July 1, 2026. While both events are disclosed, the principal action emphasized in the Item 5.02 disclosure is the appointment of Shomali, which includes detailed biographical information and her effective date. The resignation is noted as non-contentious and without disagreement. The appointment of a new director to the board is a material governance event affecting the composition of the Company's leadership and oversight structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-02
Item 5.02
Six Flags appointed Mark Pauls as Chief Operating Officer effective July 15, 2026, succeeding Tim Fisher. Pauls' compensation package includes a $600,000 base salary and $1,560,000 annual equity grant target, with comprehensive severance provisions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's principal financial officer and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointment of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC (the sponsor) on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the two new appointments to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Kathryn Masci and Daniel Plourde as Co-Chief Financial Officers of Grayscale Investments Sponsors, LLC on an interim basis, effective July 2, 2026, with Ms. Masci also appointed as Principal Financial and Accounting Officer of the registrant and as a member of the Board of Managers. While the filing also mentions Edward McGee's departure, the principal disclosed action centers on the appointment of two named executives to critical financial leadership roles. This is material as it affects the registrant's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-01
Item 8.01
Andrew D. Walker has been promoted to Executive Vice President, Chief Customer Operations Officer, representing a material elevation in title and scope of responsibility within the company's executive leadership. The disclosure emphasizes his expanded portfolio of operational and transformation functions, making this a significant executive appointment that would affect a reasonable investor's assessment of the company's leadership structure and operational direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-01
Item 5.02
Williams Companies appointed two independent directors, Robb E. Turner and Lloyd W. (Billy) Helms, Jr., to its Board of Directors effective July 1, 2026, expanding the Board from ten to twelve members. Both appointees will receive annual compensation of $130,000 in cash retainer and $200,000 in RSU equity retainer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-01
Item 5.02
Rocco F. Arcuri, Sr. was appointed as a director of Arrow Financial Corporation and as Senior Vice President, Regional President, Mohawk Valley of Arrow Bank, effective July 1, 2026, following the completion of the Adirondack acquisition. The appointment reflects leadership integration from the acquired entity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-01
Item 5.02
Nathan E. Baxter was appointed President & Chief Executive Officer effective June 26, 2026, and elected to the Board of Directors. While the filing also discloses James Hagedorn's departure as CEO and Chairman (and his severance arrangements), the principal disclosed action centers on Baxter's appointment to the top executive role and board seat, which is the forward-looking leadership change. The appointment is material as it represents a significant succession event at the company's helm after Hagedorn's 25-year tenure as CEO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-01
Item 5.02
The Board appointed Damian A. Ribar as Executive Vice President and Chief Operating Officer, effective July 20, 2026. While the disclosure includes compensatory details (base salary of $500,000, equity awards, and bonus eligibility), the principal disclosed action is the appointment of a named executive officer to a C-suite role. The compensation terms are ancillary to the appointment itself.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-01
Item 7.01
Ramesh Srinivasan was appointed to the executive officer position of Executive Vice President, Chief Strategy Officer, effective August 1, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-01
Item 5.02
The filing discloses the appointment of Bruce Hausmann as a director of Mativ Holdings, effective July 1, 2026, to fill a newly created board vacancy. The Board increased from 6 to 7 members and appointed Hausmann as a Class I director with a term expiring at the 2029 Annual Meeting. He was also appointed to the Audit Committee and qualifies as an "audit committee financial expert." This is a clear executive appointment event, material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-01
Item 5.02
The disclosure centers on the appointment of Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer of Rigel Pharmaceuticals, effective July 1, 2026. While the filing also mentions Dr. Hannah's concurrent resignation from the Board and the departure of the prior CMO, Lisa Rojkjaer, the principal action disclosed is the appointment of a named executive officer to a C-suite position. This is material to investors as it affects the Company's senior leadership and medical strategy.
View raw filing on EDGAR →